Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica

ilustraciones

Autores:
Ortiz Cano, Natalia Andrea
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/79686
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/79686
https://repositorio.unal.edu.co/
Palabra clave:
510 - Matemáticas::519 - Probabilidades y matemáticas aplicadas
610 - Medicina y salud::615 - Farmacología y terapéutica
Farmacología - Estadísticas
Meta-análisis
Meta-análisis en red
Revisión sistemática
Efectividad farmacológica
Seguridad farmacológica
Network meta-analysis
Systematic review
Pharmacological effectiveness
Pharmacological safety
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional
id UNACIONAL2_d70a16701b59f2e1766f68815e51fbed
oai_identifier_str oai:repositorio.unal.edu.co:unal/79686
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
dc.title.translated.eng.fl_str_mv Evaluation of the statistical methodology applied to network meta-analysis to compare the effectiveness and safety of a pharmacological intervention.
title Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
spellingShingle Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
510 - Matemáticas::519 - Probabilidades y matemáticas aplicadas
610 - Medicina y salud::615 - Farmacología y terapéutica
Farmacología - Estadísticas
Meta-análisis
Meta-análisis en red
Revisión sistemática
Efectividad farmacológica
Seguridad farmacológica
Network meta-analysis
Systematic review
Pharmacological effectiveness
Pharmacological safety
title_short Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
title_full Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
title_fullStr Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
title_full_unstemmed Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
title_sort Evaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológica
dc.creator.fl_str_mv Ortiz Cano, Natalia Andrea
dc.contributor.advisor.none.fl_str_mv Ramírez Guevara, Isabel Cristina
González Álvarez, Nelfi Gertrudis
dc.contributor.author.none.fl_str_mv Ortiz Cano, Natalia Andrea
dc.subject.ddc.spa.fl_str_mv 510 - Matemáticas::519 - Probabilidades y matemáticas aplicadas
610 - Medicina y salud::615 - Farmacología y terapéutica
topic 510 - Matemáticas::519 - Probabilidades y matemáticas aplicadas
610 - Medicina y salud::615 - Farmacología y terapéutica
Farmacología - Estadísticas
Meta-análisis
Meta-análisis en red
Revisión sistemática
Efectividad farmacológica
Seguridad farmacológica
Network meta-analysis
Systematic review
Pharmacological effectiveness
Pharmacological safety
dc.subject.lemb.none.fl_str_mv Farmacología - Estadísticas
Meta-análisis
dc.subject.proposal.spa.fl_str_mv Meta-análisis en red
Revisión sistemática
Efectividad farmacológica
Seguridad farmacológica
dc.subject.proposal.eng.fl_str_mv Network meta-analysis
Systematic review
Pharmacological effectiveness
Pharmacological safety
description ilustraciones
publishDate 2020
dc.date.issued.none.fl_str_mv 2020-02-19
dc.date.accessioned.none.fl_str_mv 2021-06-23T15:12:04Z
dc.date.available.none.fl_str_mv 2021-06-23T15:12:04Z
dc.type.spa.fl_str_mv Trabajo de grado - Maestría
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TM
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/79686
dc.identifier.instname.spa.fl_str_mv Universidad Nacional - Sede Medellín
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/79686
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional - Sede Medellín
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv Agresti, A., y Klingenberg, B. (2005). Multivariate tests comparing binomial probabilities, with application to safety studies for drugs. Journal of the Royal Statistical Society: Series C (Applied Statistics), 54 (4), 691{706.
Akl, E. A., Sun, X., Busse, J. W., Johnston, B. C., Briel, M., Mulla, S., . . . others (2012). Speci c instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. Journal of clinical epidemiology, 65 (3), 262{267.
Al Khalifah, R., Florez, I. D., Guyatt, G., y Thabane, L. (2018). Network meta-analysis: users' guide for pediatricians. BMC pediatrics, 18 (1), 180.
Amariles, P., Hincapi e, J., Jim enez, C., Guti errez, F., y Giraldo, N. (2011). Farmacoseguridad: farmacovigilancia y seguimiento farmacoterap eutico. Grupo de Investigaci on Promoci on y Prevenci on Farmac eutica. Medell n: Universidad de Antioquia.
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., . . . others (2009). Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology, 20 (5), 1103{1112.
Austin, H., Klippel, J., Balow, J., Le Riche, N., Steinberg, A., Plotz, P., y Decker, J. (s.f.). Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs.
Baker, S. G., y Kramer, B. S. (2002). The transitive fallacy for randomized trials: if a bests b and b bests c in separate trials, is a better than c? BMC Medical Research Methodology, 2 (1), 13.
Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., y Li, L.-S. (2008). Successful treatment of class v+ iv lupus nephritis with multitarget therapy. Journal of the American Society of Nephrology, 19 (10), 2001{2010.
Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H., . . . others (2012). Joint european league against rheumatism and european renal association{european dialysis and transplant association (eular/era-edta) recommendations for the management of adult and paediatric lupus nephritis. Annals of the rheumatic diseases, 71 (11), 1771{1782.
Bomback, A. S., Appel, G. B., y Pisetsky, D. S. (2017). Diagnosis and classi cation of renal disease in systemic lupus erythematosus. Waltham, MA: UpToDate.
Borenstein, M., Hedges, L. V., Higgins, J. P., y Rothstein, H. R. (2011). Introduction to meta-analysis. John Wiley & Sons.
Boumpas, D. T., Austin III, H., Balow, J., Vaughan, E., Yarboro, C., Klippel, J., y Steinberg, A. (1992). Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The lancet, 340 (8822), 741{745. Buccheri, S., Sodeck, G. H., y Capodanno, D. (2018). Statistical primer: methodology and reporting of meta-analyses. European Journal of Cardio-Thoracic Surgery, 53 (4), 708{713.
Bucher, H. C., Guyatt, G. H., Gri th, L. E., y Walter, S. D. (1997). The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology, 50 (6), 683{691.
Cade, R., Spooner, G., Schlein, E., Pickering, M., De Quesada, A., Holcomb, A., . . . others (1973). Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron, 10 (1), 37{56.
Catalá, F., y Tobías, A. (2013). Síntesis de la evidencia clínica y meta-análisis en red con comparaciones indirectas. Medicina Clínica, 140 (4), 182{187.
Chan, T. M., Li, F. K., Tang, C. S., Wong, R. W., Fang, G. X., Ji, Y. L., . . . others (2000). E cacy of mycophenolate mofetil in patients with di use proliferative lupus nephritis. New England Journal of Medicine, 343 (16), 1156{1162.
Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., . . . others (2011). Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. American journal of kidney diseases, 57 (2), 235{244.
Cipriani, A., Higgins, J. P., Geddes, J. R., y Salanti, G. (2013). Conceptual and technical challenges in network meta-analysis. Annals of internal medicine, 159 (2), 130{137.
Cochran, W. G. (1954). The combination of estimates from di erent experiments. Biometrics, 10 (1), 101{129.
Contreras, G., Pardo, V., Cely, C., Borja, E., Hurtado, A., De La Cuesta, C., . . . others (2005). Factors associated with poor outcomes in patients with lupus nephritis. Lupus, 14 (11), 890{895.
DerSimonian, R., y Laird, N. (1986). Meta-analysis in clinical trials. Controlled clinical trials, 7 (3), 177{188.
Dias, S., Ades, A. E., Welton, N. J., Jansen, J. P., y Sutton, A. J. (2018). Network metaanalysis for decision-making. John Wiley & Sons.
Dias, S., Sutton, A. J., Ades, A., y Welton, N. J. (2013). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Medical Decision Making, 33 (5), 607{617.
Dias, S., Sutton, A. J., Ades, A., y Welton, N. J. (2013). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Medical Decision Making, 33 (5), 607{617.
Dias, S., Welton, N., Caldwell, D., y Ades, A. (2010). Checking consistency in mixed treatment comparison meta-analysis. Statistics in medicine, 29 (7-8), 932{944.
Dias, S., Welton, N. J., Sutton, A. J., Caldwell, D. M., Lu, G., y Ades, A. (2011). Nice dsu technical support document 4: Inconsistency in networks of evidence based on randomised controlled trials.
Donadio Jr, J., Holley, K., Ferguson, R., y Ilstrup, D. (1976). Progressive lupus glomerulonephritis. treatment with prednisone and combined prednisone and cyclophosphamide. En Mayo clinic proceedings (Vol. 51, pp. 484{494).
Donadio Jr, J. V., Holley, K. E., Wagoner, R. D., Ferguson, R. H., y McDu e, F. C. (1972). Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Annals of Internal Medicine, 77 (6), 829{835.
Dyadyk, A., Vasilenko, I., Bagriy, A., Dyadyk, O., Yarovaya, N., Roschin, Y., y cols. (2001). Azathioprine and cyclophosphamide in treatment of patients with di use proliferative lupus nephritis-a randomized controlled study. Nephrol Dial Transplant, 16 (6), A57.
Efthimiou, O., Debray, T. P., van Valkenhoef, G., Trelle, S., Panayidou, K., Moons, K. G., . . . Group, G. M. R. (2016). Getreal in network meta-analysis: a review of the methodology. Research synthesis methods, 7 (3), 236{263.
El-Sehemy, M. S., Al-Saaran, A. M., Baddour, N. M., Adam, A. G., y Moez, P. E. (2006). Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. The Egyptian journal of immunology, 13 (1), 39.
El-Shafey, E. M., Abdou, S. H., y Shareef, M. M. (2010). Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in egyptian patients? Clinical and experimental nephrology, 14 (3), 214{221.
Fries, M., Kracht, K., Li, J., Munsaka, M., Sanchez-Kam, M., Singh, K., . . . Whalen, K. Z. (2016). Safety monitoring methodology in the premarketing setting. JSM Proc, 2247{ 2269.
Furie, R., Nicholls, K., Cheng, T.-T., Houssiau, F., Burgos-Vargas, R., Chen, S.-L., . . . Merrill, J. T. (2014). E cacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis & rheumatology, 66 (2), 379{389.
Garc a-Perdomo, H. A., y Tob as, A. (2016). Metan alisis en red: comparaciones indirectas y mixtas, un nuevo m etodo al servicio de la epidemiolog a cl nica y la salud p ublica. Revista Peruana de Medicina Experimental y Salud P ublica, 33 , 149{153.
Gelman, A., Rubin, D. B., y cols. (1992). Inference from iterative simulation using multiple sequences. Statistical science, 7 (4), 457{472.
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., . . . others (2005). Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New England Journal of Medicine, 353 (21), 2219{2228.
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., . . . Steinberg, A. D. (1996). Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Annals of internal medicine, 125 (7), 549{557.
Grootscholten, C., Ligtenberg, G., van Houwelingen, H., y cols. (2004). Randomized controlled trial comparing cyclophosphamide pulse therapy with azathioprine/methylprednisolone in proliferative lupus nephritis [abstract no. su-fc047]. American Society of Nephrology Renal Week.
Group, A. T. (2014). Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination e cacy and safety study. Arthritis & Rheumatology, 66 (11), 3096{3104.
Guyatt, G., Cairns, J., Churchill, D., Cook, D., Haynes, B., Hirsh, J., . . . others (1992). Evidence-based medicine: a new approach to teaching the practice of medicine. Jama, 268 (17), 2420{2425.
Hahn, B. H., Kantor, O. S., y Osterland, C. K. (1975). Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Annals of internal medicine, 83 (5), 597{605.
Hasselblad. (1998). Meta-analysis of multitreatment studies. Medical Decision Making, 18 (1), 37{43.
Higgins, J., Altman, D., Sterne, J., y cols. (2011). Assessing risk of bias in included studies. in: Higgins jpt, green s (editors). cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011). the cochrane collaboration, 2011. Disponible en: www.handbook.cochrane.org.
Higgins, J., Jackson, D., Barrett, J., Lu, G., Ades, A., y White, I. (2012). Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research synthesis methods, 3 (2), 98{110.
Higgins, J. P., Altman, D. G., G tzsche, P. C., J uni, P., Moher, D., Oxman, A. D., . . . Sterne, J. A. (2011). The cochrane collaboration's tool for assessing risk of bias in randomised trials. Bmj, 343 , d5928.
Higgins, J. P., y Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21 (11), 1539{1558.
Higgins, J. P., Thompson, S. G., Deeks, J. J., y Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ: British Medical Journal, 327 (7414), 557.
Hong, R., Haijin, Y., Xianglin, W., Cuilan, H., y Nan, C. (2007). A preliminary study of tacrolimus versus cyclophosphamide in patients with di use proliferative lupus nephritis. En Nephrology dialysis transplantation (Vol. 22, pp. 276{276).
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. d. R., Danieli, M. G., . . . others (2002). Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46 (8), 2121{2131.
Hutton, B., Catala-Lopez, F., y Moher, D. (2016). The prisma statement extension for systematic reviews incorporating network meta-analysis: Prisma-nma. Medicina clinica, 147 (6), 262.
Idoate, A., y Idoipe, A. (2002). Investigaci on y ensayos cl nicos. Farmacia hospitalaria, 1 , 325{344.
IntHout, J., Ioannidis, J. P., y Borm, G. F. (2014). The hartung-knapp-sidik-jonkman method for random e ects meta-analysis is straightforward and considerably outperforms the standard dersimonian-laird method. BMC medical research methodology, 14 (1), 25.
Jayne, D., Appel, G., Chan, T., Barkay, H., Weiss, R., y Wofsy, D. (2013). Lb0003 a randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Annals of the Rheumatic Diseases, 72 (Suppl 3), A164{A164.
Kamanamool, N., Ingsathit, A., Rattanasiri, S., Ngamjanyaporn, P., Kasitanont, N., Chawanasuntorapoj, R., . . . others (2018). Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus, 27 (4), 647{656.
Krahn, U., Binder, H., y K onig, J. (2013). A graphical tool for locating inconsistency in network meta-analyses. BMC medical research methodology, 13 (1), 35.
Lau, J. (2007). Evidence-based medicine and meta-analysis: Getting more out of the literature. En R. A. Greenes (Ed.), Clinical decision support (p. 249-264). Burlington: Academic Press.
Lazcano, E., Salazar-Mart nez, E., Guti errez-Castrell on, P., Angeles-Llerenas, A., Hern andez-Gardu~no, A., y Viramontes, J. L. (2004). Ensayos cl nicos aleatorizados: variantes, m etodos de aleatorizaci on, an alisis, consideraciones eticas y regulaci on. Salud p ublica de M exico, 46 (6), 559{584.
Ledesma, R., Macbeth, G., y Cortada De Kohan, N. (2008). E ect size: A conceptual review and applications with the vista statistical system. Revista Latinoamericana de Psicolog a, 40 (3), 425{439.
Lee, Y. H., y Song, G. G. (2015). Relative e cacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a bayesian network meta-analysis of randomized controlled trials. Lupus, 24 (14), 1520{1528.
Li, X., Ren, H., Zhang, Q., Zhang, W., Wu, X., Xu, Y., . . . Chen, N. (2012). Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrology Dialysis Transplantation, 27 (4), 1467{ 1472.
Liang, M. H., Schur, P. H., Fortin, P., St. Clair, E. W., Balow, J. E., Costenbader, K., . . . others (2006). The american college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis & Rheumatism: O cial Journal of the American College of Rheumatology, 54 (2), 421{ 432.
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., . . . others (2015). Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Annals of internal medicine, 162 (1), 18{26.
Lu, G., y Ades, A. (2004). Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in medicine, 23 (20), 3105{3124.
Lu, G., y Ades, A. E. (2006). Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association, 101 (474), 447-459. doi: 10.1198/016214505000001302
Lu, G.,Welton, N. J., Higgins, J. P. T., White, I. R., y Ades, A. E. (2011). Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. Research Synthesis Methods, 2 (1), 43-60.
Lui, S., Cheng, I., Tong, K., Li, C., Wong, K., Chang, D., y cols. (1997). Treatment of type iv lupus nephritis (ln)|comparison of 2 triple therapy regimens: cyclosporin a (csa), prednisolone (pred), azathioprine (aza) vs. oral cyclophosphamide (pocp), prednisolone, azathioprine. Nephrology, 3 (Suppl 1), S476.
Lumley. (2002). Network meta-analysis for indirect treatment comparisons. Statistics In Medicine, 21 (16), 2313{2324.
Mbuagbaw, L., Rochwerg, B., Jaeschke, R., Heels-Andsell, D., Alhazzani, W., Thabane, L., y Guyatt, G. H. (2017). Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic reviews, 6 (1), 1{5.
Mehra, S., Usdadiya, J. B., Jain, V. K., Misra, D. P., y Negi, V. S. (2018). Comparing the e cacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatology International, 38 (4), 557{568.
Mendonca, S., Gupta, D., Ali, S., Gupta, P., y cols. (2017). Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? a singlecenter experience. Saudi Journal of Kidney Diseases and Transplantation, 28 (5), 1069.
Mitwalli, A. H., Al Wakeel, J. S., Hurraib, S., Aisha, A., Al Suwaida, A., Alam, A., . . . others (2011). Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi Journal of Kidney Diseases and Transplantation, 22 (5), 935.
Mok, C. C., Ying, K. Y., Yim, C. W., Siu, Y. P., Tong, K. H., To, C. H., y Ng, W. L. (2016). Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Annals of the rheumatic diseases, 75 (1), 30{36.
Mulic-Bacic, S., Antic, D., Krizic, M., Hajdarovic, A., y Mulic, E. (2008). Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis. Annals of the rheumatic diseases, 67 (Suppl II), 349.
Mysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., . . . others (2013). E cacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase iii study. Arthritis & Rheumatism, 65 (9), 2368{2379.
Ong, L. M., Hooi, L. S., Lim, T. O., Goh, B. L., Ahmad, G., Ghazalli, R., . . . others (2005). Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology, 10 (5), 504{510.
Palmer, S. C., Tunnicli e, D. J., Singh-Grewal, D., Mavridis, D., Tonelli, M., Johnson, D. W., . . . Strippoli, G. F. (2017). Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. American Journal of Kidney Diseases, 70 (3), 324{336.
Peñaranda, L. F. P. (2014). Lupus nephropathy. Revista Colombiana de Nefrología, 1 (2), 104{117.
Perrone, F., Di Maio, M., De Maio, E., Maione, P., Ottaiano, A., Pensabene, M., . . . Gallo, C. (2003). Statistical design in phase ii clinical trials and its application in breast cancer. The Lancet Oncology, 4 (5), 305{311.
Puhan, M. A., Sch unemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., . . . Guyatt, G. H. (2014). A grade working group approach for rating the quality of treatment e ect estimates from network meta-analysis. Bmj, 349 , g5630.
R Core Team. (2020). R: A language and environment for statistical computing [Manual de software inform atico]. Vienna, Austria. Descargado de https://www.R-project.org/
Rathi, M., Sharma, A., Goyal, A., Jaryal, A., Gupta, P. K., y Gupta, K. L. (2014). Randomized controlled trial of low-dose intravenous cyclophosphamide versus oral mycophenolate mofetil in treatment of lupus nephritis. Indian Journal of Rheumatology(9), S6.
Richardson, W. S., Wilson, M. C., Nishikawa, J., Hayward, R. S., y cols. (1995). The wellbuilt clinical question: a key to evidence-based decisions. Acp j club, 123 (3), A12{3.
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez-Guerrero, J., . . . others (2012). E cacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis & Rheumatism, 64 (4), 1215{1226.
Rovin, B. H., Solomons, N., Pendergraft III, W. F., Dooley, M. A., Tumlin, J., Romero- Diaz, J., . . . others (2019). A randomized, controlled double-blind study comparing the e cacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney international, 95 (1), 219{231.
R ucker, G. (2012). Network meta-analysis, electrical networks and graph theory. Research synthesis methods, 3 (4), 312{324.
R ucker, G., y Schwarzer, G. (2014). Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in network meta-analysis. Statistics in Medicine, 33 (25), 4353{4369.
Rúcker, G., y Schwarzer, G. (2015). Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC medical research methodology, 15 (1), 58.
R[ucker, G., Schwarzer, G., Carpenter, J. R., y Schumacher, M. (2008). Undue reliance on i 2 in assessing heterogeneity may mislead. BMC medical research methodology, 8 (1), 79.
Ruiz Irastorza, G., Espinosa, G., Frutos, M. A., Jim enez Alonso, J., Praga, M., Pallar es, L., . . . Quereda, C. (2012). Diagn ostico y tratamiento de la nefritis l upica: Documento de consenso del grupo de enfermedades autoinmunes sist emicas (geas) de la sociedad espa~nola de medicina interna (semi) y de la sociedad espa~nola de nefrolog a (sen). Nefrolog a (Madrid), 32 , 1{35.
Salanti, G. (2012a). Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many bene ts, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods, 3 (2), 80-97.
Salanti, G. (2012b). Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many bene ts, many concerns for the next generation evidence synthesis tool. Research synthesis methods, 3 (2), 80{97.
Salanti, G., Ades, A., y Ioannidis, J. P. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology, 64 (2), 163{171.
Salanti, G., Higgins, J. P., Ades, A., y Ioannidis, J. P. (2008). Evaluation of networks of randomized trials. Statistical methods in medical research, 17 (3), 279{301.
Sandoya, E. (2008). Meta-an alisis: fortalezas y debilidades. Revista Uruguaya de Cardiolog a, 23 (3), 263{275.
Schwarzer, G., Carpenter, J. R., y R ucker, G. (2015). Meta-analysis with r (Vol. 4784). Springer.
Sedhain, A., Hada, R., Agrawal, R. K., Bhattarai, G. R., y Baral, A. (2018). Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in nepalese population: a randomized control trial. BMC nephrology, 19 (1), 175.
Sesso, R., Monteiro, M., Sato, E., Kirsztajn, G., Silva, L., y Ajzen, H. (1994). A controlled trial of pulse cydophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus, 3 (2), 107{112.
Singh, J. A., Hossain, A., Kotb, A., y Wells, G. A. (2016). Comparative e ectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic reviews, 5 (1), 155.
Sun, J., Zhang, H., Ji, Y., Gui, M., Yi, B., Wang, J., y Jiang, J. (2015). E cacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class iv lupus nephritis. International journal of clinical and experimental medicine, 8 (11), 21572.
Tian, S. Y., Feldman, B. M., Beyene, J., Brown, P. E., Uleryk, E. M., y Silverman, E. D. (2014). Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. The Journal of Rheumatology, 41 (10), 1998{2007.
Tonin, F. S., Rotta, I., Mendes, A. M., y Pontarolo, R. (2017). Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharmacy Practice (Granada), 15 (1).
Tunnicli e, D. J., Palmer, S. C., Henderson, L., Masson, P., Craig, J. C., Tong, A., . . . others (2018). Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database of Systematic Reviews(6).
van Valkenhoef, G., Dias, S., Ades, A., yWelton, N. J. (2016). Automated generation of nodesplitting models for assessment of inconsistency in network meta-analysis. Research synthesis methods, 7 (1), 80{93.
Van Valkenhoef, G., y Kuiper, J. (2020). Gemtc: Network meta-analysis using bayesian methods. R package version 0.8{6 .
Van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A., y Welton, N. J. (2012). Automating network meta-analysis. Research synthesis methods, 3 (4), 285{299.
Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., . . . Salanti, G. (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis. Research synthesis methods, 7 (1), 55{79.
White, I. R. (2015). Network meta-analysis. The Stata Journal, 15 (4), 951{985.
White, I. R., Barrett, J. K., Jackson, D., y Higgins, J. P. (2012b). Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research synthesis methods, 3 (2), 111{125.
White, I. R., Barrett, J. K., Jackson, D., y Higgins, J. P. T. (2012a). Consistency and inconsistency in network meta-analysis: model estimation using multivariate metaregression. Research Synthesis Methods, 3 (2), 111{125.
Whitehead, A. (2002). Meta-analysis of controlled clinical trials (Vol. 7). John Wiley & Sons.
Yee, C., Gordon, C., Dostal, C., Petera, P., Dadoniene, J., Gri ths, B., . . . others (2004). Eular randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Annals of the rheumatic diseases, 63 (5), 525{529.
Zhang, M., Qi, C., Zha, Y., Chen, J., Luo, P., Wang, L., . . . others (2019). Le unomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in chinese patients: a randomized trial. Clinical Rheumatology, 38 (3), 859{867.
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.spa.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
Acceso abierto
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 113 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Medellín - Ciencias - Maestría en Ciencias - Estadística
dc.publisher.department.spa.fl_str_mv Escuela de estadística
dc.publisher.faculty.spa.fl_str_mv Facultad de Ciencias
dc.publisher.place.spa.fl_str_mv Medellín
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Medellín
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/79686/4/license.txt
https://repositorio.unal.edu.co/bitstream/unal/79686/6/license_rdf
https://repositorio.unal.edu.co/bitstream/unal/79686/5/1128468515.2020.pdf
https://repositorio.unal.edu.co/bitstream/unal/79686/7/1128468515.2020.pdf.jpg
bitstream.checksum.fl_str_mv cccfe52f796b7c63423298c2d3365fc6
4460e5956bc1d1639be9ae6146a50347
daf99865629342dc437e266b4d7714d4
86e6521972032333f6117f1f53326322
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814089454241972224
spelling Atribución-NoComercial-SinDerivadas 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Acceso abiertoinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Ramírez Guevara, Isabel Cristina80caa9b3424cdd3848e2e720fe73f6a1González Álvarez, Nelfi Gertrudis01ecd23c35a3bdb21599e31a7238b442600Ortiz Cano, Natalia Andrea4144683296787c3dbfbb6a823b402d796002021-06-23T15:12:04Z2021-06-23T15:12:04Z2020-02-19https://repositorio.unal.edu.co/handle/unal/79686Universidad Nacional - Sede MedellínRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustracionesLa medicina basada en la evidencia tiene por objetivo el uso consciente de la mejor evidencia clínica disponible, para lo cual incorporó la revisión sistemática y el meta-análisis como técnicas de resumen que permiten sintetizar la información de grandes volúmenes de publicaciones para un mismo problema de salud. La revisión sistemática reúne toda la evidencia clínica disponible acerca del problema a abordar de una manera estandarizada, explícita y reproducible para luego con el meta-análisis combinar cuantitativamente los resultados provenientes de esta evidencia clínica; sin embargo, el meta-análisis solo permite comparar dos intervenciones farmacológicas al mismo tiempo, por tanto, no resultaría efectivo en aquellos casos en los que se cuenta con más de una intervención farmacológica para la misma enfermedad. En vista de esta desventaja, en los últimos años se ha desarrollado una nueva metodología denominada meta-análisis en red, que permite comparar todos las intervenciones farmacológicas disponibles en la red de evidencia y adicionalmente realizar comparaciones indirectas cuando dos intervenciones farmacológicas no se han comparado directamente en un ensayo clínico. Los modelos estadísticos a utilizar dependen de si los datos están disponibles a nivel de paciente o a nivel de estudio y de la homogeneidad de los resultados a comparar. En este trabajo, se describieron los modelos e inferencias estadísticas usadas (frecuentistas y bayesianos) en el meta-análisis en red y se aplicaron algunos de ellos para identificar cuál de los tratamientos farmacológicos disponibles para el tratamiento de inducción de la nefritis lúpica proliferativa es el más efectivo y seguro. El protocolo inherente al meta-análisis en red del presente trabajo se encuentra registrado, revisado y publicado en la base de datos PROSPERO con el número CDR42018102861. Tanto la metodología bayesiana como frecuentista conllevaron a las mismas inferencias estadísticas y los resultados obtenidos, aunque no permitieron dar una respuesta única a la pregunta de investigación aportan información relevante para tomar una decisión informada de riesgo-beneficio según las necesidades del paciente y los tratamientos que se encuentran disponibles. (Tomado de la fuente)The objective of evidence-based medicine is the conscious use of the best available clinical evidence, for which it incorporated the systematic review and meta-analysis as summary techniques that allow the synthesis of information from large volumes of publications for the same health problem. The systematic review gathers all the available clinical evidence about the problem to be addressed in a standardized, explicit and reproducible way, and then with the meta-analysis, quantitatively combine the results from this clinical evidence; However, the meta-analysis only allows two pharmacological interventions to be compared at the same time, therefore, it would not be effective in those cases where there is more than one pharmacological intervention for the same disease. In view of this disadvantage, in recent years, a new methodology called network meta-analysis has been developed, which makes it possible to compare all the pharmacological interventions available in the evidence network and additionally make indirect comparisons when two pharmacological interventions have not been directly compared in a clinical trial. The statistical models to be used depend on whether the data are available at the patient level or at the study level and on the homogeneity of the results to be compared. In this work, the statistical models and inferences (frequentist and Bayesian) used in the network meta-analysis were described and some of them were applied to identify which of the pharmacological treatments available for the induction treatment of proliferative lupus nephritis is the most effective and safe. The protocol inherent to the network meta-analysis of this work is registered, revised and published in the PROSPERO database with the number CDR42018102861. Both the Bayesian and frequentist methodology led to the same statistical inferences and the results obtained, although they did not allow a single answer to the research question, they provide relevant information to make an informed risk-benefit decision according to the needs of the patient and the treatments that are available. (Tomado de la fuente)MaestríaMagíster en Ciencias - Estadística113 páginasapplication/pdfspaUniversidad Nacional de ColombiaMedellín - Ciencias - Maestría en Ciencias - EstadísticaEscuela de estadísticaFacultad de CienciasMedellínUniversidad Nacional de Colombia - Sede Medellín510 - Matemáticas::519 - Probabilidades y matemáticas aplicadas610 - Medicina y salud::615 - Farmacología y terapéuticaFarmacología - EstadísticasMeta-análisisMeta-análisis en redRevisión sistemáticaEfectividad farmacológicaSeguridad farmacológicaNetwork meta-analysisSystematic reviewPharmacological effectivenessPharmacological safetyEvaluación de la metodología estadística aplicada al meta-análisis en red para realizar la comparación de la efectividad y seguridad de una intervención. farmacológicaEvaluation of the statistical methodology applied to network meta-analysis to compare the effectiveness and safety of a pharmacological intervention.Trabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMAgresti, A., y Klingenberg, B. (2005). Multivariate tests comparing binomial probabilities, with application to safety studies for drugs. Journal of the Royal Statistical Society: Series C (Applied Statistics), 54 (4), 691{706.Akl, E. A., Sun, X., Busse, J. W., Johnston, B. C., Briel, M., Mulla, S., . . . others (2012). Speci c instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. Journal of clinical epidemiology, 65 (3), 262{267.Al Khalifah, R., Florez, I. D., Guyatt, G., y Thabane, L. (2018). Network meta-analysis: users' guide for pediatricians. BMC pediatrics, 18 (1), 180.Amariles, P., Hincapi e, J., Jim enez, C., Guti errez, F., y Giraldo, N. (2011). Farmacoseguridad: farmacovigilancia y seguimiento farmacoterap eutico. Grupo de Investigaci on Promoci on y Prevenci on Farmac eutica. Medell n: Universidad de Antioquia.Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., . . . others (2009). Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology, 20 (5), 1103{1112.Austin, H., Klippel, J., Balow, J., Le Riche, N., Steinberg, A., Plotz, P., y Decker, J. (s.f.). Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs.Baker, S. G., y Kramer, B. S. (2002). The transitive fallacy for randomized trials: if a bests b and b bests c in separate trials, is a better than c? BMC Medical Research Methodology, 2 (1), 13.Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., y Li, L.-S. (2008). Successful treatment of class v+ iv lupus nephritis with multitarget therapy. Journal of the American Society of Nephrology, 19 (10), 2001{2010.Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H., . . . others (2012). Joint european league against rheumatism and european renal association{european dialysis and transplant association (eular/era-edta) recommendations for the management of adult and paediatric lupus nephritis. Annals of the rheumatic diseases, 71 (11), 1771{1782.Bomback, A. S., Appel, G. B., y Pisetsky, D. S. (2017). Diagnosis and classi cation of renal disease in systemic lupus erythematosus. Waltham, MA: UpToDate.Borenstein, M., Hedges, L. V., Higgins, J. P., y Rothstein, H. R. (2011). Introduction to meta-analysis. John Wiley & Sons.Boumpas, D. T., Austin III, H., Balow, J., Vaughan, E., Yarboro, C., Klippel, J., y Steinberg, A. (1992). Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The lancet, 340 (8822), 741{745. Buccheri, S., Sodeck, G. H., y Capodanno, D. (2018). Statistical primer: methodology and reporting of meta-analyses. European Journal of Cardio-Thoracic Surgery, 53 (4), 708{713.Bucher, H. C., Guyatt, G. H., Gri th, L. E., y Walter, S. D. (1997). The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology, 50 (6), 683{691.Cade, R., Spooner, G., Schlein, E., Pickering, M., De Quesada, A., Holcomb, A., . . . others (1973). Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron, 10 (1), 37{56.Catalá, F., y Tobías, A. (2013). Síntesis de la evidencia clínica y meta-análisis en red con comparaciones indirectas. Medicina Clínica, 140 (4), 182{187.Chan, T. M., Li, F. K., Tang, C. S., Wong, R. W., Fang, G. X., Ji, Y. L., . . . others (2000). E cacy of mycophenolate mofetil in patients with di use proliferative lupus nephritis. New England Journal of Medicine, 343 (16), 1156{1162.Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., . . . others (2011). Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. American journal of kidney diseases, 57 (2), 235{244.Cipriani, A., Higgins, J. P., Geddes, J. R., y Salanti, G. (2013). Conceptual and technical challenges in network meta-analysis. Annals of internal medicine, 159 (2), 130{137.Cochran, W. G. (1954). The combination of estimates from di erent experiments. Biometrics, 10 (1), 101{129.Contreras, G., Pardo, V., Cely, C., Borja, E., Hurtado, A., De La Cuesta, C., . . . others (2005). Factors associated with poor outcomes in patients with lupus nephritis. Lupus, 14 (11), 890{895.DerSimonian, R., y Laird, N. (1986). Meta-analysis in clinical trials. Controlled clinical trials, 7 (3), 177{188.Dias, S., Ades, A. E., Welton, N. J., Jansen, J. P., y Sutton, A. J. (2018). Network metaanalysis for decision-making. John Wiley & Sons.Dias, S., Sutton, A. J., Ades, A., y Welton, N. J. (2013). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Medical Decision Making, 33 (5), 607{617.Dias, S., Sutton, A. J., Ades, A., y Welton, N. J. (2013). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Medical Decision Making, 33 (5), 607{617.Dias, S., Welton, N., Caldwell, D., y Ades, A. (2010). Checking consistency in mixed treatment comparison meta-analysis. Statistics in medicine, 29 (7-8), 932{944.Dias, S., Welton, N. J., Sutton, A. J., Caldwell, D. M., Lu, G., y Ades, A. (2011). Nice dsu technical support document 4: Inconsistency in networks of evidence based on randomised controlled trials.Donadio Jr, J., Holley, K., Ferguson, R., y Ilstrup, D. (1976). Progressive lupus glomerulonephritis. treatment with prednisone and combined prednisone and cyclophosphamide. En Mayo clinic proceedings (Vol. 51, pp. 484{494).Donadio Jr, J. V., Holley, K. E., Wagoner, R. D., Ferguson, R. H., y McDu e, F. C. (1972). Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Annals of Internal Medicine, 77 (6), 829{835.Dyadyk, A., Vasilenko, I., Bagriy, A., Dyadyk, O., Yarovaya, N., Roschin, Y., y cols. (2001). Azathioprine and cyclophosphamide in treatment of patients with di use proliferative lupus nephritis-a randomized controlled study. Nephrol Dial Transplant, 16 (6), A57.Efthimiou, O., Debray, T. P., van Valkenhoef, G., Trelle, S., Panayidou, K., Moons, K. G., . . . Group, G. M. R. (2016). Getreal in network meta-analysis: a review of the methodology. Research synthesis methods, 7 (3), 236{263.El-Sehemy, M. S., Al-Saaran, A. M., Baddour, N. M., Adam, A. G., y Moez, P. E. (2006). Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. The Egyptian journal of immunology, 13 (1), 39.El-Shafey, E. M., Abdou, S. H., y Shareef, M. M. (2010). Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in egyptian patients? Clinical and experimental nephrology, 14 (3), 214{221.Fries, M., Kracht, K., Li, J., Munsaka, M., Sanchez-Kam, M., Singh, K., . . . Whalen, K. Z. (2016). Safety monitoring methodology in the premarketing setting. JSM Proc, 2247{ 2269.Furie, R., Nicholls, K., Cheng, T.-T., Houssiau, F., Burgos-Vargas, R., Chen, S.-L., . . . Merrill, J. T. (2014). E cacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis & rheumatology, 66 (2), 379{389.Garc a-Perdomo, H. A., y Tob as, A. (2016). Metan alisis en red: comparaciones indirectas y mixtas, un nuevo m etodo al servicio de la epidemiolog a cl nica y la salud p ublica. Revista Peruana de Medicina Experimental y Salud P ublica, 33 , 149{153.Gelman, A., Rubin, D. B., y cols. (1992). Inference from iterative simulation using multiple sequences. Statistical science, 7 (4), 457{472.Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., . . . others (2005). Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New England Journal of Medicine, 353 (21), 2219{2228.Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., . . . Steinberg, A. D. (1996). Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Annals of internal medicine, 125 (7), 549{557.Grootscholten, C., Ligtenberg, G., van Houwelingen, H., y cols. (2004). Randomized controlled trial comparing cyclophosphamide pulse therapy with azathioprine/methylprednisolone in proliferative lupus nephritis [abstract no. su-fc047]. American Society of Nephrology Renal Week.Group, A. T. (2014). Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination e cacy and safety study. Arthritis & Rheumatology, 66 (11), 3096{3104.Guyatt, G., Cairns, J., Churchill, D., Cook, D., Haynes, B., Hirsh, J., . . . others (1992). Evidence-based medicine: a new approach to teaching the practice of medicine. Jama, 268 (17), 2420{2425.Hahn, B. H., Kantor, O. S., y Osterland, C. K. (1975). Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Annals of internal medicine, 83 (5), 597{605.Hasselblad. (1998). Meta-analysis of multitreatment studies. Medical Decision Making, 18 (1), 37{43.Higgins, J., Altman, D., Sterne, J., y cols. (2011). Assessing risk of bias in included studies. in: Higgins jpt, green s (editors). cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011). the cochrane collaboration, 2011. Disponible en: www.handbook.cochrane.org.Higgins, J., Jackson, D., Barrett, J., Lu, G., Ades, A., y White, I. (2012). Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research synthesis methods, 3 (2), 98{110.Higgins, J. P., Altman, D. G., G tzsche, P. C., J uni, P., Moher, D., Oxman, A. D., . . . Sterne, J. A. (2011). The cochrane collaboration's tool for assessing risk of bias in randomised trials. Bmj, 343 , d5928.Higgins, J. P., y Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21 (11), 1539{1558.Higgins, J. P., Thompson, S. G., Deeks, J. J., y Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ: British Medical Journal, 327 (7414), 557.Hong, R., Haijin, Y., Xianglin, W., Cuilan, H., y Nan, C. (2007). A preliminary study of tacrolimus versus cyclophosphamide in patients with di use proliferative lupus nephritis. En Nephrology dialysis transplantation (Vol. 22, pp. 276{276).Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. d. R., Danieli, M. G., . . . others (2002). Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46 (8), 2121{2131.Hutton, B., Catala-Lopez, F., y Moher, D. (2016). The prisma statement extension for systematic reviews incorporating network meta-analysis: Prisma-nma. Medicina clinica, 147 (6), 262.Idoate, A., y Idoipe, A. (2002). Investigaci on y ensayos cl nicos. Farmacia hospitalaria, 1 , 325{344.IntHout, J., Ioannidis, J. P., y Borm, G. F. (2014). The hartung-knapp-sidik-jonkman method for random e ects meta-analysis is straightforward and considerably outperforms the standard dersimonian-laird method. BMC medical research methodology, 14 (1), 25.Jayne, D., Appel, G., Chan, T., Barkay, H., Weiss, R., y Wofsy, D. (2013). Lb0003 a randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Annals of the Rheumatic Diseases, 72 (Suppl 3), A164{A164.Kamanamool, N., Ingsathit, A., Rattanasiri, S., Ngamjanyaporn, P., Kasitanont, N., Chawanasuntorapoj, R., . . . others (2018). Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus, 27 (4), 647{656.Krahn, U., Binder, H., y K onig, J. (2013). A graphical tool for locating inconsistency in network meta-analyses. BMC medical research methodology, 13 (1), 35.Lau, J. (2007). Evidence-based medicine and meta-analysis: Getting more out of the literature. En R. A. Greenes (Ed.), Clinical decision support (p. 249-264). Burlington: Academic Press.Lazcano, E., Salazar-Mart nez, E., Guti errez-Castrell on, P., Angeles-Llerenas, A., Hern andez-Gardu~no, A., y Viramontes, J. L. (2004). Ensayos cl nicos aleatorizados: variantes, m etodos de aleatorizaci on, an alisis, consideraciones eticas y regulaci on. Salud p ublica de M exico, 46 (6), 559{584.Ledesma, R., Macbeth, G., y Cortada De Kohan, N. (2008). E ect size: A conceptual review and applications with the vista statistical system. Revista Latinoamericana de Psicolog a, 40 (3), 425{439.Lee, Y. H., y Song, G. G. (2015). Relative e cacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a bayesian network meta-analysis of randomized controlled trials. Lupus, 24 (14), 1520{1528.Li, X., Ren, H., Zhang, Q., Zhang, W., Wu, X., Xu, Y., . . . Chen, N. (2012). Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrology Dialysis Transplantation, 27 (4), 1467{ 1472.Liang, M. H., Schur, P. H., Fortin, P., St. Clair, E. W., Balow, J. E., Costenbader, K., . . . others (2006). The american college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis & Rheumatism: O cial Journal of the American College of Rheumatology, 54 (2), 421{ 432.Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., . . . others (2015). Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Annals of internal medicine, 162 (1), 18{26.Lu, G., y Ades, A. (2004). Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in medicine, 23 (20), 3105{3124.Lu, G., y Ades, A. E. (2006). Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association, 101 (474), 447-459. doi: 10.1198/016214505000001302Lu, G.,Welton, N. J., Higgins, J. P. T., White, I. R., y Ades, A. E. (2011). Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. Research Synthesis Methods, 2 (1), 43-60.Lui, S., Cheng, I., Tong, K., Li, C., Wong, K., Chang, D., y cols. (1997). Treatment of type iv lupus nephritis (ln)|comparison of 2 triple therapy regimens: cyclosporin a (csa), prednisolone (pred), azathioprine (aza) vs. oral cyclophosphamide (pocp), prednisolone, azathioprine. Nephrology, 3 (Suppl 1), S476.Lumley. (2002). Network meta-analysis for indirect treatment comparisons. Statistics In Medicine, 21 (16), 2313{2324.Mbuagbaw, L., Rochwerg, B., Jaeschke, R., Heels-Andsell, D., Alhazzani, W., Thabane, L., y Guyatt, G. H. (2017). Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic reviews, 6 (1), 1{5.Mehra, S., Usdadiya, J. B., Jain, V. K., Misra, D. P., y Negi, V. S. (2018). Comparing the e cacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatology International, 38 (4), 557{568.Mendonca, S., Gupta, D., Ali, S., Gupta, P., y cols. (2017). Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? a singlecenter experience. Saudi Journal of Kidney Diseases and Transplantation, 28 (5), 1069.Mitwalli, A. H., Al Wakeel, J. S., Hurraib, S., Aisha, A., Al Suwaida, A., Alam, A., . . . others (2011). Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi Journal of Kidney Diseases and Transplantation, 22 (5), 935.Mok, C. C., Ying, K. Y., Yim, C. W., Siu, Y. P., Tong, K. H., To, C. H., y Ng, W. L. (2016). Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Annals of the rheumatic diseases, 75 (1), 30{36.Mulic-Bacic, S., Antic, D., Krizic, M., Hajdarovic, A., y Mulic, E. (2008). Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis. Annals of the rheumatic diseases, 67 (Suppl II), 349.Mysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., . . . others (2013). E cacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase iii study. Arthritis & Rheumatism, 65 (9), 2368{2379.Ong, L. M., Hooi, L. S., Lim, T. O., Goh, B. L., Ahmad, G., Ghazalli, R., . . . others (2005). Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology, 10 (5), 504{510.Palmer, S. C., Tunnicli e, D. J., Singh-Grewal, D., Mavridis, D., Tonelli, M., Johnson, D. W., . . . Strippoli, G. F. (2017). Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. American Journal of Kidney Diseases, 70 (3), 324{336.Peñaranda, L. F. P. (2014). Lupus nephropathy. Revista Colombiana de Nefrología, 1 (2), 104{117.Perrone, F., Di Maio, M., De Maio, E., Maione, P., Ottaiano, A., Pensabene, M., . . . Gallo, C. (2003). Statistical design in phase ii clinical trials and its application in breast cancer. The Lancet Oncology, 4 (5), 305{311.Puhan, M. A., Sch unemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., . . . Guyatt, G. H. (2014). A grade working group approach for rating the quality of treatment e ect estimates from network meta-analysis. Bmj, 349 , g5630.R Core Team. (2020). R: A language and environment for statistical computing [Manual de software inform atico]. Vienna, Austria. Descargado de https://www.R-project.org/Rathi, M., Sharma, A., Goyal, A., Jaryal, A., Gupta, P. K., y Gupta, K. L. (2014). Randomized controlled trial of low-dose intravenous cyclophosphamide versus oral mycophenolate mofetil in treatment of lupus nephritis. Indian Journal of Rheumatology(9), S6.Richardson, W. S., Wilson, M. C., Nishikawa, J., Hayward, R. S., y cols. (1995). The wellbuilt clinical question: a key to evidence-based decisions. Acp j club, 123 (3), A12{3.Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez-Guerrero, J., . . . others (2012). E cacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis & Rheumatism, 64 (4), 1215{1226.Rovin, B. H., Solomons, N., Pendergraft III, W. F., Dooley, M. A., Tumlin, J., Romero- Diaz, J., . . . others (2019). A randomized, controlled double-blind study comparing the e cacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney international, 95 (1), 219{231.R ucker, G. (2012). Network meta-analysis, electrical networks and graph theory. Research synthesis methods, 3 (4), 312{324.R ucker, G., y Schwarzer, G. (2014). Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in network meta-analysis. Statistics in Medicine, 33 (25), 4353{4369.Rúcker, G., y Schwarzer, G. (2015). Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC medical research methodology, 15 (1), 58.R[ucker, G., Schwarzer, G., Carpenter, J. R., y Schumacher, M. (2008). Undue reliance on i 2 in assessing heterogeneity may mislead. BMC medical research methodology, 8 (1), 79.Ruiz Irastorza, G., Espinosa, G., Frutos, M. A., Jim enez Alonso, J., Praga, M., Pallar es, L., . . . Quereda, C. (2012). Diagn ostico y tratamiento de la nefritis l upica: Documento de consenso del grupo de enfermedades autoinmunes sist emicas (geas) de la sociedad espa~nola de medicina interna (semi) y de la sociedad espa~nola de nefrolog a (sen). Nefrolog a (Madrid), 32 , 1{35.Salanti, G. (2012a). Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many bene ts, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods, 3 (2), 80-97.Salanti, G. (2012b). Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many bene ts, many concerns for the next generation evidence synthesis tool. Research synthesis methods, 3 (2), 80{97.Salanti, G., Ades, A., y Ioannidis, J. P. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology, 64 (2), 163{171.Salanti, G., Higgins, J. P., Ades, A., y Ioannidis, J. P. (2008). Evaluation of networks of randomized trials. Statistical methods in medical research, 17 (3), 279{301.Sandoya, E. (2008). Meta-an alisis: fortalezas y debilidades. Revista Uruguaya de Cardiolog a, 23 (3), 263{275.Schwarzer, G., Carpenter, J. R., y R ucker, G. (2015). Meta-analysis with r (Vol. 4784). Springer.Sedhain, A., Hada, R., Agrawal, R. K., Bhattarai, G. R., y Baral, A. (2018). Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in nepalese population: a randomized control trial. BMC nephrology, 19 (1), 175.Sesso, R., Monteiro, M., Sato, E., Kirsztajn, G., Silva, L., y Ajzen, H. (1994). A controlled trial of pulse cydophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus, 3 (2), 107{112.Singh, J. A., Hossain, A., Kotb, A., y Wells, G. A. (2016). Comparative e ectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic reviews, 5 (1), 155.Sun, J., Zhang, H., Ji, Y., Gui, M., Yi, B., Wang, J., y Jiang, J. (2015). E cacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class iv lupus nephritis. International journal of clinical and experimental medicine, 8 (11), 21572.Tian, S. Y., Feldman, B. M., Beyene, J., Brown, P. E., Uleryk, E. M., y Silverman, E. D. (2014). Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. The Journal of Rheumatology, 41 (10), 1998{2007.Tonin, F. S., Rotta, I., Mendes, A. M., y Pontarolo, R. (2017). Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharmacy Practice (Granada), 15 (1).Tunnicli e, D. J., Palmer, S. C., Henderson, L., Masson, P., Craig, J. C., Tong, A., . . . others (2018). Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database of Systematic Reviews(6).van Valkenhoef, G., Dias, S., Ades, A., yWelton, N. J. (2016). Automated generation of nodesplitting models for assessment of inconsistency in network meta-analysis. Research synthesis methods, 7 (1), 80{93.Van Valkenhoef, G., y Kuiper, J. (2020). Gemtc: Network meta-analysis using bayesian methods. R package version 0.8{6 .Van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A., y Welton, N. J. (2012). Automating network meta-analysis. Research synthesis methods, 3 (4), 285{299.Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., . . . Salanti, G. (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis. Research synthesis methods, 7 (1), 55{79.White, I. R. (2015). Network meta-analysis. The Stata Journal, 15 (4), 951{985.White, I. R., Barrett, J. K., Jackson, D., y Higgins, J. P. (2012b). Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research synthesis methods, 3 (2), 111{125.White, I. R., Barrett, J. K., Jackson, D., y Higgins, J. P. T. (2012a). Consistency and inconsistency in network meta-analysis: model estimation using multivariate metaregression. Research Synthesis Methods, 3 (2), 111{125.Whitehead, A. (2002). Meta-analysis of controlled clinical trials (Vol. 7). John Wiley & Sons.Yee, C., Gordon, C., Dostal, C., Petera, P., Dadoniene, J., Gri ths, B., . . . others (2004). Eular randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Annals of the rheumatic diseases, 63 (5), 525{529.Zhang, M., Qi, C., Zha, Y., Chen, J., Luo, P., Wang, L., . . . others (2019). Le unomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in chinese patients: a randomized trial. Clinical Rheumatology, 38 (3), 859{867.EspecializadaLICENSElicense.txtlicense.txttext/plain; charset=utf-83964https://repositorio.unal.edu.co/bitstream/unal/79686/4/license.txtcccfe52f796b7c63423298c2d3365fc6MD54CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://repositorio.unal.edu.co/bitstream/unal/79686/6/license_rdf4460e5956bc1d1639be9ae6146a50347MD56ORIGINAL1128468515.2020.pdf1128468515.2020.pdfTesis de Maestría en Ciencias - Estadísticaapplication/pdf3453232https://repositorio.unal.edu.co/bitstream/unal/79686/5/1128468515.2020.pdfdaf99865629342dc437e266b4d7714d4MD55THUMBNAIL1128468515.2020.pdf.jpg1128468515.2020.pdf.jpgGenerated Thumbnailimage/jpeg5227https://repositorio.unal.edu.co/bitstream/unal/79686/7/1128468515.2020.pdf.jpg86e6521972032333f6117f1f53326322MD57unal/79686oai:repositorio.unal.edu.co:unal/796862023-07-29 23:04:07.201Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Publicaciones similares